A systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

The following contains links to social media websites including Bluesky, X, TikTok, Instagram, Facebook, and LinkedIn. "Make ...

Although reports of vision problems with weight loss drugs are still rare, researchers say there is cause for concern because ...

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...

As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

A small percentage have had vision problems, but a direct causal link with the drugs has not been established.

Katz also stated that they are not recommending anyone stop using GLP-1 drugs or not use these drugs if they’re recommended by their doctor. “What we are recommending is that if you experience ...

The beverage giant is ready to manage, mitigate and adjust to the “dynamic macro environment,” including potential tariffs ...